Pharming’s angioedema drug found to be effective in open label studies
The positive results are from the treatment of 123 acute hereditary angioedema (HAE) attacks in 64 patients with different doses of Rhucin in the ongoing European and North
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).
Upstream’s proprietary drug discovery platform utilizes chemoinformatics which combines chemistry and computer-aided design to accelerate the speed and reduce the cost of discovering drugs to treat disease. Testing